I am a graduate of Industrial and Business Service Management. I have been investing and writing about biotechnology stocks for many years now and have extensive experience writing about the science and companies themselves. I am a contributor to
more I am a graduate of Industrial and Business Service Management. I have been investing and writing about biotechnology stocks for many years now and have extensive experience writing about the science and companies themselves. I am a contributor to
TalkMarkets and
Seeking Alpha. You can also follow me on
Stocktwits or
Twitter. I look for Pharmaceutical companies that are bringing new science to life that will be able to treat a variety of today's diseases and in which patients don't have many options. I look for the innovation of new drug compounds.
less
Latest Comments
Finally A Real Cancer Diagnosis Breakthrough?
yes good for both investors and for shareholders of the company. Will start to improve as more territories are commercialized.
Finally A Real Cancer Diagnosis Breakthrough?
It is quite interesting, if they can pull it off in good fashion commercially they have a shot to do great things.
Finally A Real Cancer Diagnosis Breakthrough?
Yes it will be good in the future to detect cancer at an earlier stage.
VistaGen Therapeutics: Interesting Prospects
That is taking one SSRI drug for 4-8 weeks then it not working, then taking another SSRI drug for 4-8 weeks and it not working etc. Then eventually following up with adding atypical antipsychotics
OncoSec Raising Its Profile In Fight Against Cancer
within six months to a year. They will try to release preliminary results of the combo by the end of the 4Q 2017
OncoSec Raising Its Profile In Fight Against Cancer
No upfront payments yet or milestones. For now Merck is providing Keytruda to Oncosec. My bet though is that if the results are good not only can Oncosec file for accelerated approval, but Merck could either partner with them on commercial launch or maybe even buy the company. Again, that is pending positive and robust data from the PISCES trial.
OncoSec Raising Its Profile In Fight Against Cancer
Such combinations might be possible with further pre-clinical research
20 Questions For NuLife Sciences CEO John B. Hollister
They seem to have something good going yes.
20 Questions For NuLife Sciences CEO John B. Hollister
from the website would be a good source.
South Korea Proposes Full Oil, Currency Blockade Of North; China Says No
That's cause China is still defending North Korea. It's like a child they refuse to punish that has gone wild.